FIELD: biotechnology.
SUBSTANCE: invention relates to a genetically modified rodent for expression of a modified rodent Acvr1 protein containing R258G, where the rodent genome contains a modified rodent Acvr1 gene within the rodent endogenous Acvr1 locus, to its cell, tissue and genome, as well as to a method for obtaining the said rodent. Also a nucleic acid for expressing a modified rodent Acvr1 protein containing R258G, where the nucleic acid contains a modified rodent Acvr1 gene is disclosed, as well as a nucleic acid construct for targeted modification of the Acvr1 gene in the rodent genome. The invention also relates to a method for producing an anti-Abeta antibody or an antigen-binding fragment thereof.
EFFECT: invention is effective for testing a candidate therapeutic compound for treatment against ectopic bone formation.
64 cl, 3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| RODENTS WITH CONDITIONAL ACVR1 MUTANT ALLELES | 2014 |
|
RU2676961C2 |
| NUCLEASE-MEDIATED TARGETING WITH LARGE TARGETING VECTORS | 2013 |
|
RU2645475C2 |
| ANIMALS WITH HUMANIZED IL-4 AND IL-4Rα | 2015 |
|
RU2788523C2 |
| ANIMALS WITH HUMANIZED IL-4 AND IL-4Rα | 2015 |
|
RU2703139C2 |
| GENETICALLY MODIFIED MHISTOCOMPATIBILITY COMPLEX MICE | 2012 |
|
RU2783984C2 |
| NON-HUMAN ANIMALS WITH A GYRATE DEFICIENCY | 2014 |
|
RU2721855C2 |
| NON-HUMAN ANIMALS HAVING A HUMANIZED PROLIFERATION-INDUCING LIGAND GENE | 2014 |
|
RU2671101C1 |
| NON-HUMAN ANIMALS HAVING A HUMANIZED B-CELL ACTIVATING FACTOR GENE | 2014 |
|
RU2670016C1 |
| ANIMALS OTHER THAN HUMANS CHARACTERIZED IN EXPANSION OF HEXANUCLEOTIDE REPEATS AT LOCUS C9orf72 | 2017 |
|
RU2760877C2 |
| NON-HUMAN ANIMALS CAPABLE OF DH-DH-REGROUPING OF DESIGNED GENE SEGMENTS AND WAYS OF THEIR USE | 2019 |
|
RU2801802C2 |
